Anti-CD19 chimeric antigen receptor (CAR)-T cell therapy vs. CD20xCD3 bispecific antibody as third- or later-line treatment in follicular lymphoma: a meta-analysis.

What was studied

This review compared CAR-T cell therapy with bispecific antibodies in follicular lymphoma. Both are advised as third-line or later treatment. The cancer had come back or had not responded to treatment. People had had at least 2 earlier lines of treatment. The team searched PubMed, Embase and Cochrane Library up to January 31, 2025. The review pooled 725 people. The main goal was how often the cancer responded.

What they found

The pooled response rate was 0.93 with CAR-T. It was 0.81 with bispecific antibodies. This gap was unlikely to be due to chance. Severe side effects of grade 3 or worse did not differ clearly between treatments. These included cytokine release syndrome, nerve harm and infection.

What it means for patients

The authors say CAR-T led to more responses than bispecific antibodies in this later-line setting. They say the side effects were comparable between the 2 kinds of care.

Why it is not certain yet

The abstract does not give results for complete response. It also gives no results for 12-month survival without cancer growth. It does not say how many studies looked at each treatment. A review can only be as good as the studies in it.

Source

Anti-CD19 chimeric antigen receptor (CAR)-T cell therapy vs. CD20xCD3 bispecific antibody as third- or later-line treatment in follicular lymphoma: a meta-analysis.

We restate facts from the source record in our own words. The original wording belongs to its publisher.